Study of Progression to Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Incidence/Management and Treatment

Completed

Conditions studied: Lung Diseases, Interstitial

In brief

The primary objective for this trial is to investigate the incidence probability of progression to Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) in patients with fibrosing ILD other than Idiopathic Pulmonary Fibrosis (IPF) in real-world setting in Japan. The secondary objective is to investigate the characteristics of procedures for management and treatment in patients with fibrosing ILD other than IPF in real-world setting in Japan.

Key facts

Study ID

NCT05875532

Run by

Boehringer Ingelheim

People needed

34960

Starts

2023-04-20

Expected to finish

2023-05-01

Last updated by the study team

2024-09-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients diagnosed with at least two fibrosing Interstitial Lung Disease (ILD) codes on different dates in the patient identification period
• Patients aged 18 years and older on the index date
• Patients for whom data for the 12 months prior to the index date can be extracted as baseline data

You may not qualify if…

• Patients grouped into the underlying disease of Idiopathic Pulmonary Fibrosis (IPF)
• Patients who have met PF-ILD progression criteria during the baseline period

Where it is running

• Boehringer Ingelheim Pharmaceuticals, Inc. — Ridgefield, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.